TOKYO – Fintech Global Capital LLC (FGC), a Japanese venture fund, is looking to raise about $50 million this year, mainly from institutional investors, to be spent on biotech companies in 2017.
TOKYO – Fintech Global Capital LLC (FGC), a Japanese venture fund, is looking to raise about $50 million this year, mainly from institutional investors, to be spent on biotech companies in 2017.
TOKYO – Taiho Pharmaceutical Co. Ltd. has formed a new venture in the U.S. backed with $50 million to search for oncology start-ups in which to invest. Taiho Ventures said it will look for companies that "discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients."
TOKYO – Taiho Pharmaceutical Co. Ltd. has formed a new venture in the U.S. backed with $50 million to search for oncology start-ups in which to invest. Taiho Ventures said it will look for companies that "discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients."
TOKYO – George Yeh, president of Taiwan Liposome Co. Inc. (TLC), told BioWorld Asia that in the coming years more trials for new drugs would take place in Asia, and that cross-country collaborations will help train a new generation of doctors in how to detect the potency and effectivity of treatments yet to reach the market.
TOKYO – George Yeh, president of Taiwan Liposome Co. Inc. (TLC), told BioWorld Today that in the coming years more trials for new drugs would take place in Asia, and that cross-country collaborations will help train a new generation of doctors in how to detect the potency and effectivity of treatments yet to reach the market.
TOKYO – In a world’s first, Japan-based Sanbio Inc. will conduct a phase II global trial into a treatment for chronic traumatic brain injury with allogeneic stem cells.
TOKYO – In a world's first, Japan-based Sanbio Inc. will conduct a phase II global trial into a treatment for chronic traumatic brain injury with allogeneic stem cells.
TOKYO – Harmonizing the regulatory environment across Asia and making it easier to get drugs to the market should be the priority for government agencies across the continent, said participants at the Drug Information Association’s Asia New Drug Conference.
TOKYO – China’s government and drug regulator is moving toward internationalization. And while the push may seem slow, the sheer number of reforms under way may be difficult to stay on top of for multinationals.
